PBF-680, an oral A1 adenosine receptor antagonist, inhibits the late allergic response (LAR) in mild-to-moderate atopic asthmatics: a Phase-IIa trial
D. Ramos-Barbon (Barcelona, Spain), N. Brienza (Barcelona, Spain), T. Bigorra Rodríguez (Barcelona, Spain), É. Mateus Medina (Barcelona, Spain), I. Gich Saladich (Barcelona, Spain), M. Puntes Rodríguez (Barcelona, Spain), R. Antonijoan Arbos (Barcelona, Spain), S. Quirce Gancedo (Madrid, Spain), N. Castro Palomino Laria (Barcelona, Spain), J. Castro Palomino Laria (Barcelona, Spain)
Source: Virtual Congress 2020 – Cutting edge science: novel molecules and mechanisms of airway diseases
Disease area: Airway diseases
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Ramos-Barbon (Barcelona, Spain), N. Brienza (Barcelona, Spain), T. Bigorra Rodríguez (Barcelona, Spain), É. Mateus Medina (Barcelona, Spain), I. Gich Saladich (Barcelona, Spain), M. Puntes Rodríguez (Barcelona, Spain), R. Antonijoan Arbos (Barcelona, Spain), S. Quirce Gancedo (Madrid, Spain), N. Castro Palomino Laria (Barcelona, Spain), J. Castro Palomino Laria (Barcelona, Spain). PBF-680, an oral A1 adenosine receptor antagonist, inhibits the late allergic response (LAR) in mild-to-moderate atopic asthmatics: a Phase-IIa trial. 4784
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you: